2. Academic Validation
  3. Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes

Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes

  • ACS Med Chem Lett. 2024 Jul 23;15(8):1191-1192. doi: 10.1021/acsmedchemlett.4c00332.
Ram W Sabnis 1
Affiliations

Affiliation

  • 1 Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
PMID: 39140057 DOI: 10.1021/acsmedchemlett.4c00332
Abstract

Provided herein are novel cyanopyridine compounds as KHK inhibitors, pharmaceutical compositions, use of such compounds in treating NAFLD, NASH, and type II diabetes, and processes for preparing such compounds.

Figures
Products